Open Angle Glaucoma
Conditions
Brief summary
To the best of Investigator knowledge, no studies to this date have compared the safety and efficacyof ologen® Collagen Matrix to MMC in exaggerated healing response among JOAG patients. Given that,filtration surgery is usually less successful in patients with juvenile glaucoma; the purpose of this study is to compare these two adjuvant therapies in exaggerated healing response among JOAG patients. Investigator hypothesis is that trabeculectomy with ologen® Collagen Matrix would be as effective as MMC in IOP control, with prominent bleb morphology as compared to MMC bleb.
Detailed description
Standard trabeculectomy All trabeculectomy surgeries will be performed under peribulbar anesthesia.Under aseptic surgical technique, superior rectus suture will be placed using 4-0 silk and a fornix-based conjunctival flap will be performed. Sub-Tenon dissection and hemostasis may be performed as required.A half-thickness 4 x 4mm rectangular/ triangular scleral flap will be dissected up to clear cornea, and a 2 × 2 mm deep scleral block will be excised and peripheral iridectomy will be performed. The scleral flap will be closed with one or two 10-0 nylon sutures and conjunctiva will be closed with 8-0 vicryl suture. Releasable sutures may be applied to the scleral flap if needed. ologen® Collagen Matrix ologen® Collagen Matrix approved by Indian health authority with registration numberof MD-1517 (valid till Mar-15-2018) will be provided by Aeon Ajanta India Pvt. Ltd. free of cost for this clinical research only. The following table summarizes the model number, shape and manufacturer of ologen® Collagen Matrix to be used in this clinical research. Product Model Shape Size Manufacturer Country of Origin Product Registration ologen® Collagen Matrix 830601 Round cylindrical 6mm (diameter) x 2mm (thickness) Aeon Astron Europe B. V. The Netherlands MD-1517 (valid till Mar-15-2018) Mitomycin C Mitomycin-C Kyowa®; Kyowa Hakko Kogyo Co., Ltd. will be used. 0.02% solution of MMC will be prepared freshly on the day of planned surgery.
Interventions
PROCEDUREologen® Collagen Matrix
Ologen is a collagen matrix used to modulate wound healing in the postoperative period to promote diffuse blebs
PROCEDURETrabeculectomy with low dose mitomycin C
Trabeculectomy with low dose MMC
Sponsors
L.V. Prasad Eye Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
ologen® Collagen Matrix, Model 830601, shape Round cylindrical, Size 6mm (diameter) x 2mm (thickness),Manufacturer Aeon Astron Europe B. V.
Eligibility
Sex/Gender
ALL
Age
10 Years to 40 Years
Healthy volunteers
No
Inclusion criteria
1. Age between 10 to 40 years (inclusive) 2. Uncontrolled IOP (defined as IOP \> 21 mm Hg) despite maximum tolerable antiglaucoma therapy 3. Open anterior chamber angle on gonioscopic examination 4. Glaucomatous optic disc damage on clinical examination (focal or diffuse neuroretinal rim thinning, localized notching or nerve fiber layer defects) with corresponding visual field (VF) defects 5. Patientor his/her guardian is willing and able to comply with study procedures and sign informed consent
Exclusion criteria
1\. Patients with steroid-induced glaucoma and other types of secondary open angle glaucoma 2. Juvenile-onset Open Angle Glaucoma eyes that underwent trabeculectomy with MMC or had a previous filtering surgery 3. Patients with any other ocular disease that may expose them to an undue risk of a significant adverse event during the course of the study, including but not limited to ocular cancer, trauma, corneal surface damage or other conditions as determined by the clinical judgment of the investigator 4. Patient with single functional eye 5. Participation in any study 30 days prior to trabeculectomy 6. Pregnant or breast-feeding women \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Intraocular pressure control in the two groups will be compared. | 1 year | Comparison of IOP control between the two groups: Assess control of IOP over time. Complete success is defined as IOP reduction of \>20% and / or an IOP constantly \<21 mmHg without any antiglaucoma medication. Qualified success is defined as IOP \< 21 mmHg with topical antiglaucoma medication. Failure is defined as IOP \> 21mmHg in 2 subsequent follow visits despite topical antiglaucoma medication. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Bleb morphology:Change of Moorfields Bleb Grading System (MBGS) score over time | at 3 months, 6 months and 1 year | Assess bleb characteristics using Moorfields Bleb Grading System (MBGS) score as measurement tool to document bleb grading score over time; and comparison of bleb morphology in the two groups with photographs and ASOCT |
Countries
India
Outcome results
None listed